FDA expands Voquenza approval for heartburn relief in non-erosive GERD (Healio)

The FDA has expanded the approval of Voquenza to include heartburn relief for patients with nonerosive gastroesophageal reflux disease (GERD). This decision is based on clinical data demonstrating the efficacy and safety of Voquenza in alleviating heartburn symptoms in this patient population. The expanded approval offers a new treatment option for individuals suffering from nonerosive GERD, addressing a significant need in gastroenterology care.